UBS Adjusts Price Target on LogicBio Therapeutics to $6.30 From $6.10, Maintains Neutral Rating
UBS Adjusts Price Target on LogicBio Therapeutics to $6.30 From $6.10, Maintains Neutral Rating
瑞銀將LogicBio Therapeutics的目標股價從6.10美元調整至6.30美元，維持中立評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間